

# **Pulmonary Arterial Hypertension Market Forecasts to 2034 – Global Analysis By Type (Innovative, Generics and Other Types), Product (Endothelin Receptor Antagonists, Soluble Guanylate Cyclase (sGC) Stimulators, Phosphodiesterase-5 (PDE-5) Inhibitors, Prostacyclin Analogs and Other Products), Route of Administration, End User and By Geography**

<https://marketpublishers.com/r/PFDBCD993B03EN.html>

Date: April 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: PFDBCD993B03EN

## **Abstracts**

According to Statistics MRC, the Global Pulmonary Arterial Hypertension Market is accounted for \$6.7 billion in 2026 and is expected to reach \$11.8 billion by 2034 growing at a CAGR of 7.4% during the forecast period. High blood pressure in the arteries supplying blood to the lungs is a defining feature of pulmonary arterial hypertension, a rare and dangerous condition. Breathing difficulties and heart failure are some of the complications that can result from this elevated pressure in the pulmonary arteries. This market includes a variety of treatments intended to control and alleviate PAH symptoms, with the ultimate goal of enhancing patients' general health and outlook.

According to The American Journal of Managed Care, PAH is a rare disorder found in 15 to 50 persons per million within the United States and Europe. Idiopathic, heritable, and anorexigen-induced PAH make up 52.6% of all PAH cases. Usually, PAH affects women aged between 30 and 60 years.

Market Dynamics:

Driver:

### Increasing prevalence of risk factors

PAH is often associated with underlying conditions such as connective tissue diseases, congenital heart defects, and liver disease, among others. As the incidence of these risk factors rises globally, so does the prevalence of PAH. Additionally, lifestyle factors such as sedentary behavior and exposure to environmental toxins contribute to the escalation of PAH cases. The aging population further amplifies the risk, as PAH is more commonly diagnosed in older individuals. This growing burden of risk factors has led to an upsurge in the number of people affected by PAH, driving the demand for innovative treatments, pharmaceutical interventions, and medical advancements.

### Restraint:

#### High costs associated with treatment options

The high cost of available treatment options is a major barrier to the pulmonary arterial hypertension market. The cost of PAH drugs, which include phosphodiesterase-5 inhibitors, endothelin receptor antagonists, and prostacyclin analogs, can be prohibitive for patients and healthcare systems alike. Optimizing disease management is made more difficult by the complex nature of PAH diagnosis and treatment, which calls for specialized healthcare infrastructure and knowledge. These financial and practical limitations make it difficult to provide effective PAH care and emphasize the need for more readily available and reasonably priced therapeutic options.

### Opportunity:

#### Development of innovative therapeutic approaches

The market for pulmonary arterial hypertension offers a number of opportunities, including the creation of novel treatment strategies and focused medications. Technological and scientific developments have made it possible to find new treatment approaches that are more effective in addressing the underlying causes of PAH. A larger patient pool may result from improved early diagnosis and raised awareness.

### Threat:

#### Limited treatment options

The market for pulmonary arterial hypertension is seriously threatened by the scarcity of

treatment options and the difficulty of creating efficient treatments. Because PAH is an uncommon and serious illness, developing new medications is difficult due to the disease's complex pathophysiology and the requirement for novel mechanisms of action. However, the lack of varied and focused treatment options could restrict patient options and impede the PAH market's overall expansion.

#### Covid-19 Impact:

The COVID-19 pandemic has influentially impacted the market. During lockdowns, patients with PAH had difficulty getting access to medical care and treatments. Patients with PAH experienced delays in diagnosis and treatment initiation due to disruptions in the healthcare system. Additionally, the pipeline of possible medications was impacted by hampered research and development efforts for novel PAH therapies. The PAH market was further strained by reallocations of healthcare resources and economic uncertainties. The pandemic's long-term effects on market dynamics and PAH management are still a worry, and solving these issues will take continued work.

The Phosphodiesterase-5 (PDE-5) Inhibitors segment is expected to be the largest during the forecast period

Phosphodiesterase-5 (PDE-5) Inhibitors segment commanded the largest share over the projected period. Phosphodiesterase-5 (PDE-5) Inhibitors like tadalafil and sildenafil are essential to the market for pulmonary arterial hypertension. These medications function by blocking the phosphodiesterase type 5 enzyme, which causes the pulmonary arteries to dilate and improve blood flow. These inhibitors lower pulmonary arterial pressure by relaxing smooth muscle cells in the pulmonary vessels by specifically targeting the PDE-5 enzyme. PDE-5 inhibitors are frequently used in combination therapy to improve treatment efficacy because they are widely used in the management of PAHs.

The generics segment is expected to have the highest CAGR during the forecast period

The generics segment is showing profitable growth over the period of time as it deals with the accessibility of generic substitutes for name-brand PAH drugs. Generic medications offer patients more affordable options since they are bioequivalent substitutes for their name-brand counterparts. This section helps make PAH therapies more accessible, which makes it possible for a larger group of patients to afford and take their prescribed drugs. These elements are boosting segments growth.

### Region with largest share:

The pulmonary arterial hypertension (PAH) market in North America is expected to hold largest share. The frequency of PAH diagnoses is on the rise, which can be attributed to advances in treatment options, enhanced diagnostic methods, and increased awareness. Furthermore, more access to cutting-edge treatments and pharmaceuticals is made possible by North America's extensive healthcare system and high healthcare spending. Moreover, a major factor in the advancement of PAH research, development, and uptake in the North American region has been the cooperative efforts of pharmaceutical companies, research institutes, and healthcare providers.

### Region with highest CAGR:

The European market for pulmonary arterial hypertension has grown consistently over a period of time. Improvements in treatment options, growing awareness among patients and healthcare professionals in diagnosis have all fueled market growth in the region. Europe also boasts a well-established healthcare infrastructure, facilitating the accessibility of these advanced treatments. Additionally, the collaborative efforts between pharmaceutical companies, research institutions, and healthcare organizations in the region have resulted in the introduction of novel drugs and therapies, further propelling regional growth.

### Key players in the market

Some of the key players in Pulmonary Arterial Hypertension market include Actelion pharmaceuticals Ltd., Bayer, Eli Lilly and company, Gilead sciences, inc., Gsk plc , Hubei Gedian Humanwell Pharmaceutical Co., Ltd, Johnson & Johnson , Lupin, Pfizer inc, Sun pharmaceutical industries Ltd., Taizhou Tianrui Chemical Co., Ltd, Teva pharmaceutical industries Ltd., United therapeutics corporation and Viatrix inc.

### Key Developments:

In December 2023, G+Flas Life Sciences and Bayer AG have signed a letter of intent (LOI) to collaborate on the development of novel Crispr genome-edited tomato varieties that are nutritionally enhanced with vitamin D3. This LOI underscores the shared interest of G+FLAS and Bayer AG in developing tomato seeds that not only meet high commercial standards but also incorporate cutting-edge genetic traits through G+Flas's Crispr genome editing technology.

In October 2023, Viartis Inc., a global healthcare company, announced it has received an offer for the divestiture of substantially all of its Over-the-Counter (OTC) business, and has entered into definitive agreements to divest its Women's Healthcare business. With this announcement the Company has delivered on its commitment to announce agreements on all planned divestitures by the end of 2023 within the Company's previously communicated range, after considering the estimated retained value.

#### Products Covered:

Endothelin Receptor Antagonists

Soluble Guanylate Cyclase (SGC) Stimulators

Phosphodiesterase-5 (PDE-5) Inhibitors

Prostacyclin Analogs

Other Products

#### Types Covered:

Innovative

Generics

Branded

Other Types

#### Route of Administrations Covered:

Oral

Intravenous/ subcutaneous

Other Routes of Administrations

**End Users Covered:**

Hospitals

Retail Pharmacies

Online Pharmacies

Other End Users

**Regions Covered:**

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments

Strategic recommendations for the new entrants

Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

#### Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

##### Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

##### Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

##### Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

## Contents

### **1 EXECUTIVE SUMMARY**

### **2 PREFACE**

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
  - 2.4.1 Data Mining
  - 2.4.2 Data Analysis
  - 2.4.3 Data Validation
  - 2.4.4 Research Approach
- 2.5 Research Sources
  - 2.5.1 Primary Research Sources
  - 2.5.2 Secondary Research Sources
  - 2.5.3 Assumptions

### **3 MARKET TREND ANALYSIS**

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Product Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19

### **4 PORTERS FIVE FORCE ANALYSIS**

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

## **5 GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY PRODUCT**

- 5.1 Introduction
- 5.2 Endothelin Receptor Antagonists
- 5.3 Soluble Guanylate Cyclase (sGC) Stimulators
- 5.4 Phosphodiesterase-5 (PDE-5) Inhibitors
- 5.5 Prostacyclin Analogs
- 5.6 Other Products

## **6 GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE**

- 6.1 Introduction
- 6.2 Innovative
- 6.3 Generics
- 6.4 Branded
- 6.5 Other Types

## **7 GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION**

- 7.1 Introduction
- 7.2 Oral
- 7.3 Intravenous
- 7.4 Other Routes of Administrations

## **8 GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY END USER**

- 8.1 Introduction
- 8.2 Hospitals
- 8.3 Retail Pharmacies
- 8.4 Online Pharmacies
- 8.5 Other End Users

## **9 GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY GEOGRAPHY**

- 9.1 Introduction
- 9.2 North America
  - 9.2.1 US
  - 9.2.2 Canada

9.2.3 Mexico

9.3 Europe

9.3.1 Germany

9.3.2 UK

9.3.3 Italy

9.3.4 France

9.3.5 Spain

9.3.6 Rest of Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 New Zealand

9.4.6 South Korea

9.4.7 Rest of Asia Pacific

9.5 South America

9.5.1 Argentina

9.5.2 Brazil

9.5.3 Chile

9.5.4 Rest of South America

9.6 Middle East & Africa

9.6.1 Saudi Arabia

9.6.2 UAE

9.6.3 Qatar

9.6.4 South Africa

9.6.5 Rest of Middle East & Africa

## **10 KEY DEVELOPMENTS**

10.1 Agreements, Partnerships, Collaborations and Joint Ventures

10.2 Acquisitions & Mergers

10.3 New Product Launch

10.4 Expansions

10.5 Other Key Strategies

## **11 COMPANY PROFILING**

11.1 Actelion Pharmaceuticals Ltd.

- 11.2 Bayer
- 11.3 Eli Lilly and company
- 11.4 Gilead Sciences, Inc.
- 11.5 Gsk Plc
- 11.6 Hubei Gedian Humanwell Pharmaceutical Co., Ltd
- 11.6 Johnson & Johnson
- 11.8 Lupin
- 11.9 Pfizer Inc
- 11.10 Sun Pharmaceutical Industries Ltd.
- 11.11 Taizhou Tianrui Chemical Co., Ltd
- 11.12 Teva Pharmaceutical Industries Ltd.
- 11.13 United Therapeutics Corporation
- 11.14 Viatris Inc

## List Of Tables

### LIST OF TABLES

- Table 1 Global Pulmonary Arterial Hypertension Market Outlook, By Region (2023–2034) (\$MN)
- Table 2 Global Pulmonary Arterial Hypertension Market Outlook, By Product (2023–2034) (\$MN)
- Table 3 Global Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2023–2034) (\$MN)
- Table 4 Global Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2023–2034) (\$MN)
- Table 5 Global Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2023–2034) (\$MN)
- Table 6 Global Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2023–2034) (\$MN)
- Table 7 Global Pulmonary Arterial Hypertension Market Outlook, By Other Products (2023–2034) (\$MN)
- Table 8 Global Pulmonary Arterial Hypertension Market Outlook, By Type (2023–2034) (\$MN)
- Table 9 Global Pulmonary Arterial Hypertension Market Outlook, By Innovative (2023–2034) (\$MN)
- Table 10 Global Pulmonary Arterial Hypertension Market Outlook, By Generics (2023–2034) (\$MN)
- Table 11 Global Pulmonary Arterial Hypertension Market Outlook, By Branded (2023–2034) (\$MN)
- Table 12 Global Pulmonary Arterial Hypertension Market Outlook, By Other Types (2023–2034) (\$MN)
- Table 13 Global Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2023–2034) (\$MN)
- Table 14 Global Pulmonary Arterial Hypertension Market Outlook, By Oral (2023–2034) (\$MN)
- Table 15 Global Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2023–2034) (\$MN)
- Table 16 Global Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2023–2034) (\$MN)
- Table 17 Global Pulmonary Arterial Hypertension Market Outlook, By End User (2023–2034) (\$MN)
- Table 18 Global Pulmonary Arterial Hypertension Market Outlook, By Hospitals

(2023–2034) (\$MN)

Table 19 Global Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2023–2034) (\$MN)

Table 20 Global Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2023–2034) (\$MN)

Table 21 Global Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2023–2034) (\$MN)

Table 22 North America Pulmonary Arterial Hypertension Market Outlook, By Country (2023–2034) (\$MN)

Table 23 North America Pulmonary Arterial Hypertension Market Outlook, By Product (2023–2034) (\$MN)

Table 24 North America Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2023–2034) (\$MN)

Table 25 North America Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2023–2034) (\$MN)

Table 26 North America Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2023–2034) (\$MN)

Table 27 North America Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2023–2034) (\$MN)

Table 28 North America Pulmonary Arterial Hypertension Market Outlook, By Other Products (2023–2034) (\$MN)

Table 29 North America Pulmonary Arterial Hypertension Market Outlook, By Type (2023–2034) (\$MN)

Table 30 North America Pulmonary Arterial Hypertension Market Outlook, By Innovative (2023–2034) (\$MN)

Table 31 North America Pulmonary Arterial Hypertension Market Outlook, By Generics (2023–2034) (\$MN)

Table 32 North America Pulmonary Arterial Hypertension Market Outlook, By Branded (2023–2034) (\$MN)

Table 33 North America Pulmonary Arterial Hypertension Market Outlook, By Other Types (2023–2034) (\$MN)

Table 34 North America Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2023–2034) (\$MN)

Table 35 North America Pulmonary Arterial Hypertension Market Outlook, By Oral (2023–2034) (\$MN)

Table 36 North America Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2023–2034) (\$MN)

Table 37 North America Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2023–2034) (\$MN)

Table 38 North America Pulmonary Arterial Hypertension Market Outlook, By End User (2023–2034) (\$MN)

Table 39 North America Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2023–2034) (\$MN)

Table 40 North America Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2023–2034) (\$MN)

Table 41 North America Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2023–2034) (\$MN)

Table 42 North America Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2023–2034) (\$MN)

Table 43 Europe Pulmonary Arterial Hypertension Market Outlook, By Country (2023–2034) (\$MN)

Table 44 Europe Pulmonary Arterial Hypertension Market Outlook, By Product (2023–2034) (\$MN)

Table 45 Europe Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2023–2034) (\$MN)

Table 46 Europe Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2023–2034) (\$MN)

Table 46 Europe Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2023–2034) (\$MN)

Table 48 Europe Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2023–2034) (\$MN)

Table 49 Europe Pulmonary Arterial Hypertension Market Outlook, By Other Products (2023–2034) (\$MN)

Table 50 Europe Pulmonary Arterial Hypertension Market Outlook, By Type (2023–2034) (\$MN)

Table 51 Europe Pulmonary Arterial Hypertension Market Outlook, By Innovative (2023–2034) (\$MN)

Table 52 Europe Pulmonary Arterial Hypertension Market Outlook, By Generics (2023–2034) (\$MN)

Table 53 Europe Pulmonary Arterial Hypertension Market Outlook, By Branded (2023–2034) (\$MN)

Table 54 Europe Pulmonary Arterial Hypertension Market Outlook, By Other Types (2023–2034) (\$MN)

Table 55 Europe Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2023–2034) (\$MN)

Table 56 Europe Pulmonary Arterial Hypertension Market Outlook, By Oral (2023–2034) (\$MN)

Table 57 Europe Pulmonary Arterial Hypertension Market Outlook, By Intravenous

(2023–2034) (\$MN)

Table 58 Europe Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2023–2034) (\$MN)

Table 59 Europe Pulmonary Arterial Hypertension Market Outlook, By End User (2023–2034) (\$MN)

Table 60 Europe Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2023–2034) (\$MN)

Table 61 Europe Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2023–2034) (\$MN)

Table 62 Europe Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2023–2034) (\$MN)

Table 63 Europe Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2023–2034) (\$MN)

Table 64 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Country (2023–2034) (\$MN)

Table 65 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Product (2023–2034) (\$MN)

Table 66 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2023–2034) (\$MN)

Table 67 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2023–2034) (\$MN)

Table 68 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2023–2034) (\$MN)

Table 69 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2023–2034) (\$MN)

Table 70 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other Products (2023–2034) (\$MN)

Table 71 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Type (2023–2034) (\$MN)

Table 72 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Innovative (2023–2034) (\$MN)

Table 73 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Generics (2023–2034) (\$MN)

Table 74 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Branded (2023–2034) (\$MN)

Table 75 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other Types (2023–2034) (\$MN)

Table 76 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2023–2034) (\$MN)

Table 77 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Oral (2023–2034) (\$MN)

Table 78 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2023–2034) (\$MN)

Table 79 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2023–2034) (\$MN)

Table 80 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By End User (2023–2034) (\$MN)

Table 81 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2023–2034) (\$MN)

Table 82 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2023–2034) (\$MN)

Table 83 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2023–2034) (\$MN)

Table 84 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2023–2034) (\$MN)

Table 85 South America Pulmonary Arterial Hypertension Market Outlook, By Country (2023–2034) (\$MN)

Table 86 South America Pulmonary Arterial Hypertension Market Outlook, By Product (2023–2034) (\$MN)

Table 86 South America Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2023–2034) (\$MN)

Table 88 South America Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2023–2034) (\$MN)

Table 89 South America Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2023–2034) (\$MN)

Table 90 South America Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2023–2034) (\$MN)

Table 91 South America Pulmonary Arterial Hypertension Market Outlook, By Other Products (2023–2034) (\$MN)

Table 92 South America Pulmonary Arterial Hypertension Market Outlook, By Type (2023–2034) (\$MN)

Table 93 South America Pulmonary Arterial Hypertension Market Outlook, By Innovative (2023–2034) (\$MN)

Table 94 South America Pulmonary Arterial Hypertension Market Outlook, By Generics (2023–2034) (\$MN)

Table 95 South America Pulmonary Arterial Hypertension Market Outlook, By Branded (2023–2034) (\$MN)

Table 96 South America Pulmonary Arterial Hypertension Market Outlook, By Other

Types (2023–2034) (\$MN)

Table 97 South America Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2023–2034) (\$MN)

Table 98 South America Pulmonary Arterial Hypertension Market Outlook, By Oral (2023–2034) (\$MN)

Table 99 South America Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2023–2034) (\$MN)

Table 100 South America Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2023–2034) (\$MN)

Table 101 South America Pulmonary Arterial Hypertension Market Outlook, By End User (2023–2034) (\$MN)

Table 102 South America Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2023–2034) (\$MN)

Table 103 South America Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2023–2034) (\$MN)

Table 104 South America Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2023–2034) (\$MN)

Table 105 South America Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2023–2034) (\$MN)

Table 106 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Country (2023–2034) (\$MN)

Table 106 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Product (2023–2034) (\$MN)

Table 108 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2023–2034) (\$MN)

Table 109 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2023–2034) (\$MN)

Table 110 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2023–2034) (\$MN)

Table 111 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2023–2034) (\$MN)

Table 112 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other Products (2023–2034) (\$MN)

Table 113 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Type (2023–2034) (\$MN)

Table 114 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Innovative (2023–2034) (\$MN)

Table 115 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Generics (2023–2034) (\$MN)

Table 116 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Branded (2023–2034) (\$MN)

Table 117 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other Types (2023–2034) (\$MN)

Table 118 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2023–2034) (\$MN)

Table 119 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Oral (2023–2034) (\$MN)

Table 120 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2023–2034) (\$MN)

Table 121 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2023–2034) (\$MN)

Table 122 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By End User (2023–2034) (\$MN)

Table 123 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2023–2034) (\$MN)

Table 124 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2023–2034) (\$MN)

Table 125 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2023–2034) (\$MN)

Table 126 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2023–2034) (\$MN)

## I would like to order

Product name: Pulmonary Arterial Hypertension Market Forecasts to 2034 – Global Analysis By Type (Innovative, Generics and Other Types), Product (Endothelin Receptor Antagonists, Soluble Guanylate Cyclase (sGC) Stimulators, Phosphodiesterase-5 (PDE-5) Inhibitors, Prostacyclin Analogs and Other Products), Route of Administration, End User and By Geography

Product link: <https://marketpublishers.com/r/PFDBCD993B03EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PFDBCD993B03EN.html>